RBC Capital Reiterates Outperform on Evolent Health, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Evolent Health (NYSE:EVH) and maintained a price target of $42.
October 08, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating on Evolent Health, maintaining a price target of $42, indicating confidence in the company's performance.
The reiteration of an Outperform rating and maintenance of a $42 price target by RBC Capital suggests continued confidence in Evolent Health's performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100